ATARA Biotherapeutics (NASDAQ: ATRA) reported Q3 EPS of ($0.90), $0.04 better than the analyst estimate of ($0.94). Revenue for the quarter came in at $5.4 million versus the consensus estimate of $3.92 million.

For earnings history and earnings-related data on ATARA Biotherapeutics (ATRA) click here.